- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 | 1 | GlobeNewswire (USA) | ||
| 12.11. | Apogee Therapeutics reports Q3 results | 1 | Seeking Alpha | ||
| 09.11. | Medizinischer Leiter von Apogee Therapeutics verkauft Aktien im Wert von 394.041 US-Dollar | 1 | Investing.com Deutsch | ||
| 24.10. | Apogee Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.10. | Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting | 3 | GlobeNewswire (USA) | ||
| 07.10. | Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now | 4 | Insider Monkey | ||
| 12.09. | Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit | 1 | GlobeNewswire (USA) | ||
| APOGEE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.09. | Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer | 113 | GlobeNewswire (Europe) | SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated... ► Artikel lesen | |
| 07.09. | Apogee Therapeutics CEO sells over $1.9 million in stock | 1 | Investing.com | ||
| 07.09. | Apogee Therapeutics CMO sells over $316k in company stock | 1 | Investing.com | ||
| 24.08. | Apogee therapeutics CFO sells shares worth over $289k | 1 | Investing.com | ||
| 19.08. | Apogee Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | Apogee Therapeutics, Inc.: Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases | 131 | GlobeNewswire (Europe) | Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in 2025... ► Artikel lesen | |
| 12.08. | Apogee Therapeutics files potential mixed shelf | 2 | Seeking Alpha | ||
| 12.08. | Apogee Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.08. | Apogee Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Apogee Therapeutics reports Q2 results | 1 | Seeking Alpha | ||
| 12.08. | Apogee Therapeutics, Inc.: Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results | 163 | GlobeNewswire (Europe) | Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week proof-of-concept data from the Phase 2 Part A trial in 2H 2025, APG808 interim Phase 1 data in... ► Artikel lesen | |
| 12.08. | Apogee Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.08. | Apogee Therapeutics CEO sells over $1.6 million in company stock | 1 | Investing.com |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,200 | +20,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,361 | -1,63 % | Defence Therapeutics Inc.: Defence Announces Closing of Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,900 | 0,00 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| RECURSION PHARMACEUTICALS | 5,695 | -0,96 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,070 | +6,32 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ONCOLYTICS BIOTECH | 0,915 | -3,17 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2024 Financial Results and Operational Highlights | BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study
Upcoming... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 16,920 | -0,88 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,936 | -3,08 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,500 | +3,83 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,160 | -0,66 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| VIR BIOTECHNOLOGY | 7,120 | +2,45 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,835 | +5,11 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,900 | +1,70 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level | ||
| ARVINAS | 25,850 | +2,95 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode | ||
| BIO-PATH | 0,810 | +1,38 % | Bio-Path-Aktie stürzt auf 52-Wochen-Tief und erreicht 0,79 US-Dollar |
APOGEE THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,05 % bei einem Aktienkurs von 43,460 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APOGEE THERAPEUTICS INC finden Sie auf Wallstreet Online.
